Clinical trials: First Line Treatment
Breast Neoplasms, Neoplasm Metastasis
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-line hormonal treatment.
- Trial name
- NCT00083993
- Testing
- Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months
- Where
- 129 sites in United States, Canada
- Volunteers
- 1,236 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Non-small Cell Lung Cancer, Postmenopausal Women
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer
This research study will test whether dual anti-estrogen therapy (anastrozole and fulvestrant) slows the time to when the cancer progresses.
- Trial name
- NCT00932152
- Testing
- fulvestrant (Faslodex), anastrozole (Arimidex), Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pittsburgh
HCC - Hepatocellular Carcinoma, Metastatic Cancer
Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy
TRIPLET HCC is a phase II-III trial that assess the effectivness of addition of ipilimumab to the combination atezolizumab-bevacizumab, on global survival and response to the treatment, for patients with advanced or metastatic…
- Conditions
- HCC - Hepatocellular Carcinoma, Metastatic Cancer, Metastatic Tumor
- Trial name
- TRIPLET (NCT05665348)
- Testing
- Ipilimumab Injection, Atezolizumab Injection, Bevacizumab
- Where
- 45 sites in France
- Volunteers
- 229 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Adenocarcinoma, Bronchiolo-Alveolar
Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma
To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.
- Trial name
- NCT00384826
- Testing
- erlotinib, paclitaxel + carboplatine
- Where
- 9 sites in France
- Volunteers
- 133 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Hepatocellular Carcinoma (HCC)
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
This study is a randomized, double-blind, multicenter, phase III clinical study to compare the efficacy and safety of HLX10 + HLX04 vs Sorafenibas as the First-line Treatment in Patients with Locally Advanced or Metastatic HCC…
- Trial name
- NCT04465734
- Testing
- HLX10, HLX04, Sorafenib
- Where
- China
- Sponsor
- Shanghai Henlius Biotech
Non-Small Cell Lung Cancer
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and…
- Trial name
- NCT02364999
- Testing
- Bevacizumab-Pfizer, Bevacizumab-EU, Paclitaxel
- Where
- 263 sites in United States, Australia and 25 more
- Volunteers
- 719 people
- Sponsor
- Pfizer
Colorectal Cancer
Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
The current clinical trials and data on the triplet regimen combined with bevacizumab for first-line treatment of metastatic colorectal cancer were from European and American populations.
- Trial name
- TRIBE-C (NCT04230187)
- Testing
- mFOLFOXIRI plus Bevacizumab, mFOLFOX6 Plus Bevacizumab
- Where
- China
- Volunteers
- 528 people
- Sponsor
- Yanhong Deng
Non-Small Cell Lung Cancer
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
The purpose of this study is to determine whether Nivolumab, Ipilimumab combined with chemotherapy is more effective than chemotherapy by itself when treating stage IV NSCLC as the first treatment given for the disease
- Trial name
- CheckMate 9LA (NCT03215706)
- Testing
- Ipilimumab, Nivolumab, Carboplatin
- Where
- 116 sites in United States, Argentina and 17 more
- Volunteers
- 719 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, Inoperable Disease
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT
This trial is designed to investigate the safety, response rates and survival outcomes of patients with inoperable lung cancer by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through…
- Trial name
- NCT06483347
- Testing
- ipilimumab+pembrolizumab or ipilimumab+durvalumab, idarubicin, bevacizumab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Helicobacter Pylori Infection
Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication
This study aims to evaluate the efficacy of vonoprazan compared with esomeprazole as first-line treatment for Helicobacter Pylori(Hp) eradication, as well as the safety and economic benefits.
- Trial name
- NCT04907747
- Testing
- Vonoprazan, Esomeprazole, Colloidal bismuth pectin
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HIV Infections
Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment
For treatment of human immunodeficiency virus type 1(HIV-1), publicly funded programmes tend to follow World Health Organization (WHO) guidelines to use a non-nucleoside reverse transcriptase inhibitor (NNRTI) combined with two…
- Trial name
- NCT02227238
- Testing
- DTG, LPV/RTV, Two NRTIs
- Where
- 59 sites in Argentina, Brazil and 11 more
- Volunteers
- 627 people
- Sponsor
- ViiV Healthcare
Lung Cancer
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00433498
- Testing
- carboplatin, cisplatin, etoposide phosphate
- Where
- 86 sites in United Kingdom
- Volunteers
- 846 people
- Sponsor
- University College, London
Helicobacter Pylori Infection
Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin
The purpose of this study is to assess and compare the effectiveness of levofloxacin-tetracycline -containing and tinidazole-tetracycline-containing quadruple regimens for the primary treatment of Helicobacter pylori infection in…
- Trial name
- NCT04122287
- Testing
- Levofloxacin, tinidazole
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Shandong University
Extensive-Stage Small Cell Lung Cancer
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
A study of adebelimab in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer
- Trial name
- NCT06614621
- Testing
- Adebrelimab +Etoposide+Platinum-based drugs, Maintenance treatment period:
- Volunteers
- 43 people
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer
S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer
This phase II trial on the assumption that S-1 combined with Leucovorin may have better efficacy and safety than simplified 5-FU/LV infusion therapy in elderly patients with advanced colorectal cancer.
- Trial name
- NCT01193452
- Testing
- S-1, Leucovorin, leucovorin, 5-fluorouracil
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
HIV-1-infection
ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance
This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in adults living with HIV-1 experiencing virological…
- Trial name
- ADORE (NCT04429152)
- Testing
- Doravirine/Lamivudine/Tenofovir
- Where
- 3 sites in South Africa
- Volunteers
- 25 people
- Sponsor
- Professor Francois Venter
Acute Promyelocytic Leukemia
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
The registry aims to compare the two first-line available treatment approaches in non-high-risk APL patients aged ≤ 70 years - ATRA plus chemotherapy and ATRA plus ATO - in terms of practitioner's choice between the two options…
- Trial name
- NCT02938858
- Where
- 27 sites in France
- Volunteers
- 400 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Colorectal Cancer
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00107315
- Testing
- bevacizumab, capecitabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Acute Lymphobkastic Leukemia, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world
The goal of this retrospective observational study is to learn about the efficacy of ponatinib in Philadelphia-positive ALL (Ph+ ALL) patients in a real-world setting.
- Trial name
- PONA4ALL Ph+ (NCT07356960)
- Volunteers
- 103 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Colorectal Neoplasms, Intestinal Neoplasms
Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)
Bevacizumab, as an antibody of vascular endothelial generated factor (VEGF), combined with the fluorouracil-based chemotherapy regimens for metastatic colorectal cancer, has become the classical first-line treatment.
- Conditions
- Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms
- Trial name
- NCT03271255
- Testing
- Apatinib Mesylate Tablets, Bevacizumab Injection
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shenzhen People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.